Adjuvant therapy (AT) with raltitrexed (RAL) in colorectal cancer (CRC) patients (pts) intolerant of 5-fluorouracil (5FU).

被引：0
|
作者：
Wilson, K. S.
Barnett, J. B.
Gill, S.
Khoo, K. E.
Fitzgerald, C. A.
机构：
[1] British Columbia Canc Agcy, Victoria, BC, Canada
[2] British Columbia Canc Agcy, Kelowna, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页码：163S / 163S
页数：1
相关论文
共 50 条
  • [1] Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia cancer agency experience
    Wilson, Kenneth S.
    Fitzgerald, Catherine A.
    Barnett, Jeff B.
    Gill, Sharlene
    Khoo, Kong E.
    CANCER INVESTIGATION, 2007, 25 (08) : 711 - 714
  • [2] Adjuvant therapy with 5-fluorouracil (5FU) plus levamisole or 5FU plus radiotherapy in resected colorectal cancer.
    Aparicio, J
    Segura, A
    Santaballa, A
    Garcerá, S
    Yuste, A
    López, P
    Tormo, A
    Reynés, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
  • [3] Does the dose of leucovorin (LV) matter with 5-fluorouracil (5FU) in colorectal cancer (CRC)?
    Biagi, James Joseph
    Coakley, Nadia
    Earle, Craig
    Erlichman, Charles
    Fields, Anthony L. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [5] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [6] Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity
    Firouzbakht, Aryan
    Renouf, Daniel John
    Chen, Leo
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Influence of 5-fluorouracil (5FU) on cancer survival in patients with microsatellite unstable (MSI) colorectal cancer
    Carethers, JM
    Smith, EJ
    Nguyen, L
    Tajima, A
    Doctolero, RT
    Cabrera, BL
    Goel, A
    Arnold, CN
    Boland, CR
    Miyai, K
    Behling, CA
    GASTROENTEROLOGY, 2002, 122 (04) : A600 - A600
  • [8] Bi-fractionated oxaliplatin (L-OHP) plus 5-fluorouracil (5FU)/leucovorin (LV) for elderly patients (pts) with advanced colorectal cancer (CRC).
    Massacesi, C
    Lippe, P
    Recchia, F
    Marcucci, F
    Rocchi, M
    Cesta, A
    Pilone, A
    Cappelletti, C
    Bonsignori, M
    Mattioli, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [9] Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)
    Goel, Gaurav
    Sehgal, Rajesh
    Meisner, Dennis James
    Sun, Min
    Pasricha, Gurleen
    Chu, Edward
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer.
    Williams, Grant Richard
    Deal, Allison Mary
    Shachar, Shlomit S.
    Walko, Christine Marie
    Patel, Jai Narendra
    O'Neil, Bert H.
    McLeod, Howard L.
    Weinberg, Marc
    Choi, Seul Ki
    Muss, Hyman B.
    Sanoff, Hanna Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345